Navigation Links
febit Receives U.S. Patent for Microfluidic Extraction Method
Date:5/27/2008

febit Expands its Leading Position in Next-Generation Sequencing

LEXINGTON, Mass. and HEIDELBERG, Germany, May 27 /PRNewswire/ -- febit today announced the receipt of US patent #7320862 on its microfluidic microarray-based method for extraction of DNA and RNA.

This method forms the basis of a novel technology that enables the expanded use of next-generation sequencers in genomic research. Further investigation of the human genome by resequencing will particularly benefit from the new method: febit uses its microfluidic biochip system for sequence-based selective isolation of nucleic acids from genomic samples. This new approach to high-throughput sequencing essentially relies on high-density microarray biochips with flexible design, a technology established by febit several years ago. The newly patented method is known as hybselect, targeted sequencing or sequence capture. Using this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing.

febit microfluidic biochip systems have been successfully used for several years in DNA analysis and synthesis. The latest patent was now granted in the US, patents in Europe and other foreign countries will soon follow.

febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips, an area where febit holds several key patents. Using a focussed application strategy, febit has been able to secure intellectual property rights on important product components, processes and evolving technologies.

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.
http://www.febit.com

Contact:

febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300 david.schull@russopartnersllc.com

eva.sterzel@febit.de wendy.lau@russopartnersllc.com


'/>"/>
SOURCE febit
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
2. febit First to Offer miRBase 11.0 Biochip
3. febit Forms Scientific Advisory Board
4. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
5. Prime Therapeutics Receives VIPPS Accreditation
6. Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries
7. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
8. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
9. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
10. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
11. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):